Blincyto®

 
Active substance Blinatumomab
Holder Amgen
Status Closed
Indication adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL)
Public documents Approbation
Information for the patient
Informed consent
Last update 11/04/2018
Last updated on 10/09/2024